Muhammad A. Khattak

Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma

Elin S. Gray, Helen Rizos, Anna Reid et al. · Oncotarget · 2015 · 322 citations · Full text

Baseline Ctdna Levels, Immunology, Pathology +18

Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial

Georgina V. Long, Jason J. Luke, Muhammad A. Khattak et al. · The Lancet Oncology · 2022 · 140 citations

Surgical Oncology, Pembrolizumab Versus Placebo, Medicine +9

Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination

Ana Arance, Luis de la Cruz‐Merino, Teresa M. Petrella et al. · Journal of Clinical Oncology · 2022 · 124 citations

Prognostic value of systemic inflammation‐based markers in advanced pancreatic cancer

Hilary Martin, K Ohara, Andrew Ddembe Kiberu et al. · Internal Medicine Journal · 2014 · 107 citations

Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy☆

C. Owen, Alexander N. Shoushtari, D Chauhan et al. · Annals of Oncology · 2020 · 106 citations · Full text

Tumor Immunology, Cancer Immunosurveillance, Medicine +7